Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.